Hi Baz, I am not entirely sure the trial is required to be taken in Japan to enable application and/or approval, different to the US in which this is customary, almost mandatory. Were you exposed to this requirements in any formal document or communication from MSB, the Japanese authorities or any other listed company?
Cell Therapy News/Articles, page-15060
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
-0.008(0.59%) |
Mkt cap ! $1.478B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $937.1K | 728.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 125280 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 5853 | 5 |
View Market Depth
| Last trade - 12.31pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |